FORM PTO-449  
PATENT & TRADEMARK OFFICEU.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
OCO1000KQSERIAL NO.:  
09/904,263INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
Rybak et al.FILING DATE:  
July 11, 2001GROUP:  
1642

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
ALH	AA	5,985,263	11/16/99	Lee et al.	424	85.2	
ALH	AB	5,951,974	09/14/99	Gilbert et al.	424	85.7	
ALH	AC	5,908,621	06/01/99	Glue et al.	424	85.7	
ALH	AD	4,766,106	08/23/88	Katre et al.	514	12	
ALH	AE	5,776,897	07/07/98	Lewis et al.	514	12	
ALH	AF	5,766,582	06/16/98	Yuen et al.	424	85.7	
ALH	AG	5,762,923	06/09/98	Gross et al.	424	85.7	
ALH	AH	5,382,427	01/17/95	Plunkett et al.	424	85.2	
ALH	AI	4,917,888	04/17/90	Katre et al.	424	85.91	
ALH	AJ	4,897,471	01/30/90	Stabinsky	536	27	
ALH	AK	4,695,623	09/22/87	Stabinsky	530	351	
ALH	AL	4,530,901	07/23/85	Weissmann	435	70	
ALH	AM	4,492,537	01/08/85	Awerkamp	417	404	
ALH	CE	5,711,944	1/27/98	Gilbert et al.	424	85.7	
ALH	CF	5,766,897	06/16/98	Braxton	435	172.1	
ALH	CG	6,363,162 B1	03/26/02	Rybak et al.	514	2	
ALH	CH	2001/0053548 A1	08/09/01	Rybak et al.	435	367	

## FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
ALH	AN	0 236 987 B1	12/28/94	EPO				
ALH	AO	0 809 996 A2	12/03/97	EPO				
ALH	AP	0 593 868 A1	04/27/94	EPO				
ALH	AQ	WO 99/48535	30/09/99	WIPO				
ALH	AR	0 510 356 A1	10/28/92	EPO				
ALH	CD	WO95/13090	05/18/95	WIPO				
ALH	CL	WO98/48840	05/11/98	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ALH	AS	Kantarjian et al., "Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options," Blood <b>87</b> :8 pp. 3069-3081, April 15, 1996						
ALH	AT	Hehlman et al., "Randomized Comparison of Interferon- $\alpha$ With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia," Blood <b>84</b> :12 pp. 4064-4077, December 15, 1994						
ALH	AU	Kantarjian et al., "Chronic Myelogenous Leukemia: A Concise Update," Blood <b>82</b> :3 pp. 691-703, August 1, 1993						
ALH	AV	Nicolaou et al., "Total Synthesis of Taxol. 1. Retrosynthesis, Degradation, and Reconstitution," J. Am. Chem. Soc. <b>117</b> pp. 624-633, 1995						
	AW	Hasford et al., "Interferon- $\alpha$ and Hydroxyurea in Early Chronic Myeloid Leukemia: A Comparative Analysis of the Italian and German Chronic Myeloid Leukemia Trials With Interferon- $\alpha$ ,"						
ALH	AX	Ozer et al., "Prolonged Subcutaneous Administration of Recombinant $\alpha$ 2b Interferon in Patients with Previously Untreated Philadelphia Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukemia: Effect on Remission Duration and Survival: Cancer and Leukemia Group B Study 8583," Blood <b>82</b> :10 pp. 2975-2984, November 15, 1993						
ALH	AY	Ohnishi et al., "A Randomized Trial Comparing Interferon- $\alpha$ With Busulfan for Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase," Blood <b>86</b> :3 pp. 906-916, August 1, 1995						

Anne L. Sullivan 1/27/03

RECEIVED  
NOV 08 2002  
TECH CENTER 1600/2900



FORM PT-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
OCO1000KQ

SERIAL NO.:

09/904, 263

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT:  
Rybak et al.FILING DATE:  
July 11, 2001GROUP:  
1642


AZ	Creagon et al., "Randomized, Surgical Adjuvant Clinical Trial of Recombinant Interferon Alfa-2a in Selected Patients With Malignant Melanoma," Journal of Clinical Oncology, <b>13</b> :13 pp. 2776-2783 November 1995
BA	Bergmann et al., "Daily Alternating Administration of High-Dose Alpha-2b-Interferon and Interleukin-2 Bolus Infusion in Metastatic Renal Cell Cancer," Cancer <b>72</b> :5, pp. 1735-1742 September 1, 1993
BB	Umeda et al., "Phase II Study of Alpha Interferon on Renal Cell Carcinoma," Cancer <b>58</b> :1231-1235, September 15, 1986
BC	Sokal et al., "Preferential Inhibition by Cytarabine of CFU-GM From Patients With Chronic Granulocytic Leukemia," Cancer <b>59</b> :197-202, January 1, 1987
BD	Fleming et al., "One-Sample Multiple Testing Procedure for Phase II Clinical Trials," Biometrics <b>38</b> :143-151 March 1982
BE	Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. <b>210</b> :4 pp. 474-485, 1989
BF	Kantarjian et al., "Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- $\alpha$ Therapy," Ann Intern Med. <b>122</b> :254-261, 1995
BG	Talpaz et al., "Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Medicine, <b>114</b> :7 April 1, 1991
BH	Négrier et al., "Intensive Regimen of Cytokines with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinoma," Journal of Immunotherapy, <b>17</b> :62-68 1995
BI	Goldman, "Optimizing Treatment for Chronic Myeloid Leukemia," The New England Journal of Medicine, <b>337</b> :4, pp. 270-271, July 24, 1997
BJ	Guilhot, et al., "Interferon Alfa-2b Combined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The New England Journal of Medicine, <b>337</b> :4 pp. 223-229, 1997.
BK	The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, <b>330</b> :12 pp.820-825, March 24, 1994
BL	Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progressive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, <b>13</b> :2 pp. 497-501 February 1995
BM	Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, <b>14</b> : 1 pp. 7-17, January 1996
BN	Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon- $\alpha$ 2b in advanced human malignancies," The Lancet, <b>335</b> pp. 1509-1512, 1990
BO	Alfonso Gennaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990
BP	Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract
BQ	Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, <b>343</b> :913-914 April 9, 1994
BR 1	Deprés-Brummer et al., "A Phase II Study of Ambulatory Chronomodulated High Dose Interferon (IFN $\alpha$ 2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, <b>15</b> :248, March 1996
BR 2	Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, <b>15</b> :248, March 1996
BR 3	Gitlitz et al., "Fluoropyrimidines Plus Interleukin-2 and Interferon- $\alpha$ in the Treatment of Metastatic Renal Cell Carcinoma: The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, <b>15</b> :248, March 1996
BS	P. Sagaster et al., "Randomised Study Using IFN- $\alpha$ versus IFN- $\alpha$ plus coumarin and cimetidine for treatment of advanced renal cell cancer," Annals of Oncology <b>6</b> :999-1003, 1995

RECEIVED

NOV 08 2002

TECH CENTER  
NOV 08 2002

Anne L. Alleran 1/27/03



FORM PT-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
OCO1000KQ

SERIAL NO.:

09/904,203

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
Rybak et al.FILING DATE:  
July 11, 2001GROUP:  
1642

(Use several sheets if necessary)

ALH	BT	D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," <i>Quality of Life Research</i> 6:103-108, 1997
ALH	BU	Sewa S. Legha, "The Role of Interferon Alfa in the Treatment of Metastatic Melanoma," <i>Seminars in Oncology</i> , 24:1 Suppl 4 (February) 1997, pp. S4-24-54-31
ALH	BV	W. Levens et al., "Long-Term Interferon Treatment in Metastatic Renal Cell Carcinoma," <i>Eur Urol.</i> 16:378-381, 1989
ALH	BW	Janice P. Dutcher, et al., "Outpatient Subcutaneous Interleukin-2 and Interferon-Alpha for Metastatic Renal Cell Cancer: Five-Year Follow-up of the Cytokine Working Group Study," <i>The Cancer Journal from Scientific American</i> 3:3 May/June 1997
ALH	BX	Talpaz et al, "Phase I Study Of Polyethylene Glycol (PEG) Interferon Alpha-2B (Intron-A) in CML Patients", <i>Blood</i> , Volume 92, Issue 10, Suppl. 1 part 1-2, 11/15, 1998, pp. 251A
ALH	BY	Talpaz et al, "Phase I Study Of Pegylated-Interferon $\alpha$ -2A (PEGASYS™) In Patients With Chronic Myelogenous Leukemia (CML)", <i>Blood</i> , Vol. 94, Issue 10, Suppl. 1, part 1, 11/15, 1999, pp.530A.
ALH	BZ	Walther P.J. et al., "Treatment of Metastatic Renal Cell Carcinoma (RCC) with Continuous Infusion 5-Fluorouracil and Interferon Alpha-2A in the Home Setting: A Phase I-II Trial", <i>Proceedings of the American Urological Association</i> , Vol. 155, May 1996 Supplement, p. 388A.
ALH	CA	Gebrosky et al., "Treatment of Renal Cell Carcinoma with 5-Fluorouracil and Alfa-Interferon", <i>Urology</i> , 50 (6) 1997, pp. 863-868.
ALH	CB	Atzpodien J. et al., "Interleukin-2 in Combination with Interferon- $\alpha$ and 5-Fluorouracil for Metastatic Renal Cell Cancer", <i>European Journal of Cancer</i> , Vol. 29A, Suppl. 5, 1993, pp. S6-S8.
EXAMINER	Anne L. Allerson	
	DATE CONSIDERED 1/27/03	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

29132\_1

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900